



Altimune to Participate at Two Upcoming Investor Conferences

May 29, 2024 at 7:31 AM EDT

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **Jefferies Global Healthcare Conference** (New York, NY)
Wednesday, June 5, 2024
Fireside Chat at 2:00 p.m. Eastern Time
- **Goldman Sachs Global Healthcare Conference** (Miami Beach, FL)
Wednesday, June 12, 2024
Fireside Chat at 9:20 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Company Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:

Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com



altimmune

Source: Altimune, Inc